Eupraxia Pharmaceuticals Up 5.5% In US Premarket As Says DiffuSphere Technology Demonstrates Targeted Drug Release

MT NewswiresNov 20 08:11 ET

Eupraxia's DiffuSphere Technology Demonstrates Targeted Drug Release While Minimizing Systemic Exposure for a Period of More Than Six Months

PR NewswireNov 20 07:00 ET

Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting

PR NewswireNov 14 17:00 ET

Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024

PR NewswireNov 13 17:00 ET

Express News | Eupraxia Pharmaceuticals Inc : Raymond James Cuts Target Price to $12 From $16.50

ReutersNov 13 07:40 ET

MT Newswires Stocks To Watch: Eupraxia Pharmaceuticals and I-80 Gold. Also Conifex, Crown; Dream Unlimited; DCM; NGEx; Peyto; Primaris REIT; VIQ Solutions

MT NewswiresNov 12 20:37 ET